ClinicalTrials.gg
CompletedNCT05014568Updated Sep 4, 2025Results posted

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults

A Phase 3 interventional study of tapinarof cream, 1% and Vehicle cream in Atopic Dermatitis, sponsored by Organon and Co. Completed at 67 sites in 2 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
407
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tapinarof in Dermatitis, Atopic — 1 open to participants now, 2 under way, 1 of them phase 3. tapinarof · Dermatitis, Atopic.

Enrollment
2nd of 12
407 · median 168
Started
2021
with 3 others
Phase 3
5 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
5 of 12
Organon and Co

Among the 12 studies testing tapinarof in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 4 that started in 2021, is one of 5 in phase 3, and was the 6th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 12 studies testing tapinarof in Dermatitis, Atopic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing tapinarof in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a double-blind, randomized, vehicle controlled Phase 3 study to evaluate the efficacy and safety of topical tapinarof cream, 1% compared to vehicle control cream in pediatric and adult subjects with atopic dermatitis.

Read the detailed description

This study is a 8-week double-blind, vehicle-controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 8 weeks. At the end of the 8-week study treatment, qualified subjects will have the option to enroll in an open-label, long-term extension study for an additional 48 weeks of treatment. Subjects who do not participate in the open-label, long-term extension study will complete a follow-up visit approximately one week after the end of treatment in this study.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • eczema
  • pediatric
  • tapinarof
  • phase 3
  • topical
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ages 2 and above with clinical diagnosis of AD
  • Subject with atopic dermatitis covering ≥5% and ≤ 35% of the BSA
  • A vIGA-AD score of ≥3 at screening and baseline
  • An EASI score of ≥6 at screening and baseline
  • Atopic dermatitis present for at least 6 months for ages 6 years old and above or 3 months for ages 2 to 5 years old
  • Female subjects of who are engaging in sexual activity that could lead to pregnancy should use acceptable methods
  • Must not be pregnant
  • Subject, subject's parent, or legal representative must be capable of giving written /assent

Exclusion criteria

Exclusion Criteria:

  • at screening
  • Chronic or acute systemic or superficial infection requiring treatment with systemic antibacterials or antifungals within one week prior to baseline visit
  • Significant dermatological or inflammatory condition other than AD that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
  • (ALT) or aspartate aminotransferase (AST) ≥2.0x the (ULN).
  • Screening total > 1.5x ULN
  • Current or chronic history of liver disease
  • Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Subjects who would not be considered suitable for topical therapy
  • Use of any prohibited medication or procedure within the indicated period before the baseline visit including other product within 30 days or 5 half-lives of the investigational product (whichever is longer)
  • History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with the subject's participation in the study, interpretation of results, or ability to understand and give .
  • Pregnant or lactating females
  • History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation
  • Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
407 participants (actual)

Study arms

  • Experimental
    tapinarof cream

    tapinarof cream, 1%, applied topically once daily

    Drug: tapinarof cream, 1%

  • Placebo comparator
    vehicle cream

    vehicle cream, applied topically once daily

    Drug: Vehicle cream

Interventions

  • applied topically once daily

  • DrugVehicle cream

    applied topically once daily

06

What researchers measure

Primary outcomes

  1. Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

    The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

Secondary outcomes

  1. Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

    The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

  2. Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.

    Assessment of percent body surface area (%BSA) is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

    Time frame: Baseline to Week 8

  3. Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

    The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

  4. Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.

    The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week. Statistics are based on 100 imputed datasets.

    Time frame: Baseline to Week 8

07

Results

Posted Sep 4, 2025

Participant flow

Participants from the main study (DMVT-505-3101) had the option to participate in the open label extension study (DMVT-505-3103, NCT05142774).

Participant flow — Overall Study
MilestoneTapinarof CreamVehicle Cream
Started270137
Completed238110
Not completed3227

Outcome measures

PrimaryPercent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

The vIGA-AD is a global assessment of the current state of the disease. It is a static 5-point scale used to grade overall disease severity (scalp excluded), as determined by the investigator, using the clinical characteristics of erythema, induration/papulation, lichenification, oozing/crusting. The vIGA-AD ranges from 0 to 4 and is calculated as Clear (0), Almost clear (1), Mild (2), Moderate (3), and Severe (4). Higher vIGA-AD scores represent more severe disease. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects Who Have a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Score of Clear or Almost Clear (0 or 1) With a Minimum 2-grade Improvement From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.45.413.9
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio, log: 2.60 · 95% CI 1.66 to 4.09Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.
SecondaryPercent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects With ≥ 75% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.55.822.9
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio, log: 2.17 · 95% CI 1.57 to 3.00Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.
SecondaryMean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.

Assessment of percent body surface area (%BSA) is an estimate of the percentage of total involved skin with atopic dermatitis. Estimates were made using the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumbs together) represented approximately 1% of the total BSA. Body regions are assigned a specific number of handprints with associated percentages (Head and neck = 10% \[10 handprints\], upper extremities = 20% \[20 handprints\], trunk (including axillae and groin) = 30% \[30 handprints\], lower extremities, including buttocks, = 40% \[40 handprints\]). Estimates of the percent involvement of each body region will be multiplied by the fraction of total body area to obtain the total %BSA involved by region and overall.

Time frame:
Baseline to Week 8
Reported as:
Mean · change in affected BSA percentage
Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.
change in affected BSA percentageTapinarof CreamVehicle Cream
Mean Change in in Percent of Total Body Surface Area (%BSA) Affected From Baseline to Week 8.-10.11 ± 0.527-4.47 ± 0.654
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · ANCOVA · p = <0.0001 · Least squares mean difference: -6.17 · 95% CI -7.69 to -4.66age\*vIGA cohort and treatment as categorical covariates, and baseline %BSA as a continuous covariate
SecondaryPercent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.

The Eczema Area and Severity Index (EASI) is a scoring system that takes into account the overall severity of disease based on lesion severity and the extent of percent body surface area affected with atopic dermatitis. The EASI is a composite score ranging from 0 -72 that takes into account the degree of erythema, edema/papulation, excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percent body surface area involved for each body region relative to the whole body. A higher EASI score represents more severe disease. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects With ≥ 90% Improvement in Eczema Area and Severity Index (EASI) From Baseline to Week 8. Analyses Were Done Using Multiple Imputation.29.86.1
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = <0.0001 · Risk ratio, log: 3.74 · 95% CI 1.98 to 7.09Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.
SecondaryPercent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.

The Peak Pruritus Numeric Rating Scale (PP-NRS) is used to quickly assess itch/pruritus severity over a 24-hour period. The PP-NRS is scored on a scale of 0 to 10, with 0 being "no itch" and 10 being "worst itch imaginable". The subject will utilize the scale to assess peak pruritis once per day and record the results in their diaries. The daily ratings are averaged to generate a score for the week. Statistics are based on 100 imputed datasets.

Time frame:
Baseline to Week 8
Reported as:
Number · Percentage of participants
Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.
Percentage of participantsTapinarof CreamVehicle Cream
Percent of Subjects ≥ 12 Years Old With a Baseline Peak Pruritis-Numeric Rating Scale (PP-NRS) Score ≥ 4 Who Achieve ≥ 4-point Reduction in the Average Weekly PP-NRS From Baseline to Week 8.55.834.2
Statistical analysis
  • Tapinarof Cream vs Vehicle Cream · Cochran-Mantel-Haenszel · p = 0.0366 · Risk ratio, log: 1.54 · 95% CI 1.03 to 2.31Adjusted logit-based estimate of the common relative risk of success (Tapinarof Cream 1%/Vehicle Cream) over all strata. Multiple imputation p-value is for null hypothesis that the log (Relative Risk) equals 0.

Adverse events

Collected over Through study completion, up to 9 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tapinarof Cream0/270 (0%)3/270 (1.1%)118/270 (43.7%)
Vehicle Cream0/137 (0%)0/137 (0%)33/137 (24.1%)
Most frequent serious events
Most frequent serious events
EventTapinarof CreamVehicle Cream
Abdominal painGastrointestinal disorders1/2700/137
Anaphylactic ShockImmune system disorders1/2700/137
Arthritis bacterialInfections and infestations1/2700/137
Most frequent other events
Showing 10 of 26
Most frequent other events
EventTapinarof CreamVehicle Cream
FolliculitisInfections and infestations22/2701/137
HeadacheNervous system disorders19/2703/137
NasopharyngitisInfections and infestations13/2707/137
Upper respiratory tract infectionInfections and infestations13/2700/137
VomitingGastrointestinal disorders10/2701/137
COVID-19Infections and infestations7/2705/137
InfluenzaInfections and infestations6/2701/137
AsthmaRespiratory, thoracic and mediastinal disorders6/2701/137
PyrexiaGeneral disorders5/2703/137
Dermatitis contactSkin and subcutaneous tissue disorders4/2703/137

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)Tapinarof CreamVehicle CreamTotal
Mean15.6 ± 16.6215.6 ± 16.4915.6 ± 16.56
Age, Customized
Age, Customized(Participants)Tapinarof CreamVehicle CreamTotal
2-6 Years7639115
7-11 Years7537112
12-17 Years6734101
≥ 18 Years522779
Sex: Female, Male
Sex: Female, Male(Participants)Tapinarof CreamVehicle CreamTotal
Female14071211
Male13066196
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tapinarof CreamVehicle CreamTotal
Hispanic or Latino544498
Not Hispanic or Latino21292304
Unknown or Not Reported415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tapinarof CreamVehicle CreamTotal
American Indian or Alaska Native202
Asian261036
Native Hawaiian or Other Pacific Islander000
Black or African American7038108
White15279231
More than one race14519
Unknown or Not Reported6511
Region of Enrollment
Region of Enrollment(Count of participants)Tapinarof CreamVehicle CreamTotal
Canada401252
United States230125355
Validated Investigator Global Assessment for Atopic Dermatitis
Validated Investigator Global Assessment for Atopic Dermatitis(Participants)Tapinarof CreamVehicle CreamTotal
0 - Clear000
1 - Almost Clear000
2 - Mild000
3 - Moderate244122366
4 - Severe261541
Percent Body Surface Area (BSA)
Percent Body Surface Area (BSA)(Percentage of Affected BSA)Tapinarof CreamVehicle CreamTotal
Mean16.45 ± 8.66617.71 ± 9.50016.87 ± 8.964

1 further baseline measures are reported on the registry.

08

Study locations

67 sites
  • Dermavant Investigative Site
    Birmingham, Alabama 35244, United States
  • Dermavant Investigative Site
    Phoenix, Arizona 85032, United States
  • Dermavant Investigative Site
    Bryant, Arkansas 72022, United States
  • Dermavant Investigative Site
    Beverly Hills, California 90212, United States
  • Dermavant Investigative Site
    Fountain Valley, California 92708, United States
  • Dermavant Investigative Site
    Fremont, California 94538, United States
  • Dermavant Investigative Site
    Inglewood, California 90301, United States
  • Dermavant Investigative Site
    Los Angeles, California 90017, United States
  • Dermavant Investigative Site
    Los Angeles, California 90033, United States
  • Dermavant Investigative Site
    Mission Viejo, California 92691, United States
  • Dermavant Investigative Site
    Sacramento, California 95815, United States
  • Dermavant Investigative Site
    Washington D.C., District of Columbia 20037, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33431, United States
  • Dermavant Investigative Site
    Boca Raton, Florida 33486, United States
  • Dermavant Investigative Site
    Brandon, Florida 33511, United States
  • Dermavant Investigative Site
    Coral Gables, Florida 33146, United States
  • Dermavant Investigative Site
    Jacksonville, Florida 32256, United States
  • Dermavant Investigative Site
    Margate, Florida 33063, United States
  • Dermavant Investigative Site
    Miami, Florida 33126, United States
  • Dermavant Investigative Site
    Miami Lakes, Florida 33014, United States
  • Dermavant Investigative Site
    Orlando, Florida 32801, United States
  • Dermavant Investigative Site
    Pinellas Park, Florida 33781, United States
  • Dermavant Investigative Site
    Sweetwater, Florida 33172, United States
  • Dermavant Investigative Site
    Tampa, Florida 33615, United States
  • Dermavant Investigative Site
    Marietta, Georgia 30060, United States
  • Dermavant Investigative Site
    Sandy Springs, Georgia 30328, United States
  • Dermavant Investigative Site
    Savannah, Georgia 31406, United States
  • Dermavant Investigative Site
    Plainfield, Indiana 46168, United States
  • Dermavant Investigative Site
    Louisville, Kentucky 40217, United States
  • Dermavant Investigative Site
    Owensboro, Kentucky 42301, United States
  • Dermavant Investigative Site
    Covington, Louisiana 70433, United States
  • Dermavant Investigative Site
    Monroe, Louisiana 71201, United States
  • Dermavant Investigative Site
    Largo, Maryland 20774, United States
  • Dermavant Investigative Site
    Bay City, Michigan 48706, United States
  • Dermavant Investigative Site
    Clarkston, Michigan 48346, United States
  • Dermavant Investigative Site
    Warren, Michigan 48088, United States
  • Dermavant Investigative Site
    Ypsilanti, Michigan 48197, United States
  • Dermavant Investigative Site
    New Brighton, Minnesota 55112, United States
  • Dermavant Investigative Site
    Missoula, Montana 59808, United States
  • Dermavant Investigative Site
    Omaha, Nebraska 68144, United States
  • Dermavant Investigative Site
    Garden City, New York 11530, United States
  • Dermavant Investigative Site
    New York, New York 10075, United States
  • Dermavant Investigative Site
    Bexley, Ohio 43209, United States
  • Dermavant Investigative Site
    Cleveland, Ohio 44106, United States
  • Dermavant Investigative Site
    Oklahoma City, Oklahoma 73071, United States
  • Dermavant Investigative Site
    Oklahoma City, Oklahoma 73120, United States
  • Dermavant Investigative Site
    Gresham, Oregon 97030, United States
  • Dermavant Investigative Site
    Portland, Oregon 97223, United States
  • Dermavant Investigative Site
    Hershey, Pennsylvania 17033, United States
  • Dermavant Investigative Site
    Greenville, South Carolina 29615, United States
  • Dermavant Investigative Site
    Knoxville, Tennessee 37909, United States
  • Dermavant Investigative Site
    Austin, Texas 78745, United States
  • Dermavant Investigative Site
    Bellaire, Texas 77401, United States
  • Dermavant Investigative Site
    Cypress, Texas 77433, United States
  • Dermavant Investigative Site
    Dallas, Texas 75230, United States
  • Dermavant Investigative Site
    Houston, Texas 77098, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78218, United States
  • Dermavant Investigative Site
    San Antonio, Texas 78229, United States
  • Dermavant Investigative Site
    Sugar Land, Texas 77479, United States
  • Dermavant Investigative Site
    Richmond, Virginia 23226, United States
  • Dermavant Investigative Site
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Dermavant Investigative Site
    Burlington, Ontario L7L 6W6, Canada
  • Dermavant Investigative Site
    Cobourg, Ontario K9A 0Z4, Canada
  • Dermavant Investigative Site
    Hamilton, Ontario L8S 1G5, Canada
  • Dermavant Investigative Site
    Oakville, Ontario L6J 7W5, Canada
  • Dermavant Investigative Site
    Ottawa, Ontario K2C 3N2, Canada
  • Dermavant Investigative Site
    Montreal, Quebec H2X 2V1, Canada
09

References and documents

Publications

  • Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, Papp KA, Browning J, Kwong P, Korman NJ, Brown PM, Rubenstein DS, Piscitelli SC, Somerville MC, Tallman AM, Kircik L. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024 Sep;91(3):457-465. doi: 10.1016/j.jaad.2024.05.023. Epub 2024 May 20. PubMed 38777187 ↗
  • Alexis AF, Kircik L, Chovatiya R, Rice ZP, Soong W, Bhutani T, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM, Armstrong AW. Tapinarof Cream for Adults and Children with Atopic Dermatitis-Efficacy by Race and Fitzpatrick Skin Type in Two Phase 3 Randomized Clinical Trials. Dermatol Ther (Heidelb). 2025 Sep;15(9):2667-2682. doi: 10.1007/s13555-025-01489-w. Epub 2025 Jul 22. PubMed 40696240 ↗
  • Gold LS, Bruno MJ, Lewitt GM, Hebert AA. Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis. J Dermatolog Treat. 2025 Dec;36(1):2517388. doi: 10.1080/09546634.2025.2517388. Epub 2025 Jul 2. PubMed 40600584 ↗
  • Bissonnette R, Stein Gold L, Kircik L, Simpson EL, Eichenfield LF, Browning J, Hebert AA, Alexis AF, Soong W, Piscitelli SC, Tallman AM, Rubenstein DS, Brown PM, Silverberg JI. Skin clearance, duration of treatment-free interval, and safety of tapinarof cream 1% once daily: Results from ADORING 3, a 48-week phase 3 open-label extension trial in adults and children down to 2 years of age with atopic dermatitis. J Am Acad Dermatol. 2025 Sep;93(3):707-714. doi: 10.1016/j.jaad.2025.05.1391. Epub 2025 May 16. PubMed 40383273 ↗
  • Gold LS, Del Rosso J, Ehst BD, Zirwas MJ, Green LJ, Brown PM, Rubenstein DS, Piscitelli SC, Tallman AM. Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials. J Dermatolog Treat. 2025 Dec;36(1):2444489. doi: 10.1080/09546634.2024.2444489. Epub 2025 Jan 12. PubMed 39799945 ↗
  • Simpson EL, Hebert AA, Browning J, Serrao RT, Sofen H, Brown PM, Piscitelli SC, Rubenstein DS, Tallman AM. Tapinarof Improved Outcomes and Sleep for Patients and Families in Two Phase 3 Atopic Dermatitis Trials in Adults and Children. Dermatol Ther (Heidelb). 2025 Jan;15(1):111-124. doi: 10.1007/s13555-024-01318-6. Epub 2025 Jan 7. PubMed 39777610 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Mar 2023, 18 months.

Results were first posted in Sep 2025, 2 years 5 months after primary completion. A results delay was requested in May 2023.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 18 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2021
First posted
Aug 20, 2021
StartActual
Sep 1, 2021
Primary completionActual
Mar 30, 2023
CompletionActual
Apr 7, 2023
Results delay requested
May 23, 2023
Results first posted
Sep 4, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05014568
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 20, 2021
Start date
Sep 1, 2021
Primary completion
Mar 30, 2023
Completion
Apr 7, 2023
Results posted
Sep 4, 2025
Last update
Sep 4, 2025

Study contacts

Diana Villalobos
study director · Dermavant Sciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion